Papel de los genes TNFA e IL10 en el desarrollo y manifestaciones clínicas de la artritis psoriásica
Revista Colombiana de Reumatología, ISSN: 0121-8123, Vol: 25, Issue: 1, Page: 9-15
2018
- 1Citations
- 450Usage
- 4Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Evaluar el impacto de los polimorfismos de los genes TNFA e IL10 y su asociación con el fenotipo clínico de la artritis psoriásica (APs). Se incluyó a 104 individuos venezolanos, no relacionados, agrupados en 52 pacientes con APs, que reunieron los criterios CASPAR, y 52 individuos sanos, sin antecedentes familiares de psoriasis. Los polimorfismos de los genes TNFA e IL10 se determinaron por PCR-SSP. El genotipo GA y alelo A del polimorfismo TNFA-238G/A parecen conferir protección contra el desarrollo de APs (OR: 0,31, IC del 95%: 0,92 -1,05, p: 0,02). El genotipo GA del polimorfismo TNFA-308G/A está asociado con una edad de inicio de APs tardía (GA = 60 ± 13,17 años vs. GG = 43,55 ± 14,29 años; p = 0,002) y el genotipo GG del polimorfismo IL10-1082A/G con un intervalo mayor entre el inicio de la psoriasis y el desarrollo de la APs (GG = 27,4 ± 24,11 años, GA = 5,47 ± 7,23 años, AA = 7,86 ± 8,51 años, p = 0,001). Los genotipos CC de IL10-819C/T e IL10-592C/A confieren riesgo de daño a las articulaciones interfalángicas distales (OR: 4,79, p = 0,026). El polimorfismo TNFA-238G/A desempeña un papel importante en el desarrollo de la APs en mestizos venezolanos. Asimismo, los polimorfismos TNFA-308G/A, IL10-1082A/G, -819C/T y -592C/A pueden modificar la expresión clínica de la APs. To evaluate the impact of polymorphisms of TNF-alpha (TNFA) and IL10 genes and their association with clinical phenotypes of psoriatic arthritis (PsA). The study included 104 unrelated Venezuelan individuals, grouped into 52 patients with PsA, who fulfilled the CASPAR criteria, and 52 healthy individuals with no family history of psoriasis. The polymorphisms of the TNFA and IL10 genes were determined by Single Specific Primer-Polymerase Chain Reaction (SSP-PCR). The GA genotype and A allele of the TNFA -238G/A polymorphism appears to confer protection against the development of PsA (OR: 0.31, 95% CI: 0.92 -1.05, P =.02). The GA genotype of the TNFA-308G/A polymorphism is associated with a late onset age of PsA (GA = 60 ± 13.17 years vs. GG = 43.55 ± 14.29 years, P =.002), and the GG genotype of the IL10 -1082A/G polymorphism with a longer time interval between the onset of psoriasis and the development of PsA (GG = 27.4 ± 24.11 years, GA = 5.47 ± 7.23 years, AA = 7.86 ± 8.51 years, P =.001). The CC genotypes of IL10-819C/T and IL10-592C/A confers risk of damage to distal interphalangeal joints (OR: 4.79, P =.026) The TNFA-238G/A polymorphism plays an important role in the development of PsA in mixed-race Venezuelans. Likewise, TNFA-308 G/A, IL10 -1082 A/G, -819C/T, -592C/A polymorphisms may modify the clinical expression of PsA.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0121812317301056; http://dx.doi.org/10.1016/j.rcreu.2017.09.002; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85044115482&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S0121812317301056; https://api.elsevier.com/content/article/PII:S0121812317301056?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0121812317301056?httpAccept=text/plain; http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232018000100009&lng=en&tlng=en; http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-81232018000100009&lng=en&tlng=en; http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232018000100009; http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-81232018000100009; https://dx.doi.org/10.1016/j.rcreu.2017.09.002
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know